P
Proteina
Revolutionizing precision medicines with a Single molecule Protein Interaction Detection platform for novel biomarker discovery
About Proteina
Proteina operates in the biotechnology sector, specializing in the discovery and development of precision medicines. The company serves pharmaceutical companies, research institutions, and healthcare providers by offering a cutting-edge Single molecule Protein Interaction Detection (SPID) platform. This platform enables the quantitative and highly reproducible analysis of protein dynamics, facilitating the discovery of novel biomarkers and therapeutic treatments. Proteina's business model revolves around providing advanced bioinformatics solutions that integrate measured data sets from multiple locations and timepoints. The company generates revenue through the sale of its SPID platform, licensing agreements, and collaborative research projects. By leveraging its proprietary technology, Proteina aims to change the paradigm in precision medicine, offering more effective and personalized treatment options.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Seoul, South Korea
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 41.8/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Biotechnology, Drug Development, Biomarkers, Techbio, Hard Tech, proteomics, DT and LS, science-based
- Technology
- Deep Tech
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPO✓Exit | Jul 2025 | $18M | — | Undisclosed | — |
| SERIES C✓Equity / VC | Jul 2021 | $16M | $64M | Mirae Asset Venture Investment · Mirae Asset Capital | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Proteina is 4.1K monthly website visits, down 50.6% over the last three months. Proteina's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Mirae Asset Venture Investment
Mirae Asset Capital
Other known investors2 additional known investors
Aju IB Investment
LB Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Proteina on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Proteina’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.